Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02457910
Title Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Enzalutamide

Enzalutamide + Taselisib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.